JP2011515498A - 抗ｈｉｖホスホインドール化合物の固体形態 - Google Patents

抗ｈｉｖホスホインドール化合物の固体形態 Download PDF

Info

Publication number
JP2011515498A
JP2011515498A JP2011502083A JP2011502083A JP2011515498A JP 2011515498 A JP2011515498 A JP 2011515498A JP 2011502083 A JP2011502083 A JP 2011502083A JP 2011502083 A JP2011502083 A JP 2011502083A JP 2011515498 A JP2011515498 A JP 2011515498A
Authority
JP
Japan
Prior art keywords
crystalline form
form according
powder diffraction
ray powder
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011502083A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515498A5 (https=
Inventor
エム． モウスサ アデル
エイチ． オ’ネイルル ミケ
シェング クイアオホング
Original Assignee
イデニク ファルマセウチカルス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イデニク ファルマセウチカルス インコーポレーテッド filed Critical イデニク ファルマセウチカルス インコーポレーテッド
Publication of JP2011515498A publication Critical patent/JP2011515498A/ja
Publication of JP2011515498A5 publication Critical patent/JP2011515498A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011502083A 2008-03-27 2009-03-27 抗ｈｉｖホスホインドール化合物の固体形態 Pending JP2011515498A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7234908P 2008-03-27 2008-03-27
US61/072,349 2008-03-27
US4384108P 2008-04-10 2008-04-10
US61/043,841 2008-04-10
US15586909P 2009-02-26 2009-02-26
US61/155,869 2009-02-26
PCT/US2009/038479 WO2009120914A1 (en) 2008-03-27 2009-03-27 Solid forms of an anti-hiv phosphoindole compound

Publications (2)

Publication Number Publication Date
JP2011515498A true JP2011515498A (ja) 2011-05-19
JP2011515498A5 JP2011515498A5 (https=) 2013-05-23

Family

ID=40791117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011502083A Pending JP2011515498A (ja) 2008-03-27 2009-03-27 抗ｈｉｖホスホインドール化合物の固体形態

Country Status (9)

Country Link
US (1) US8470870B2 (https=)
EP (1) EP2276771A1 (https=)
JP (1) JP2011515498A (https=)
AU (1) AU2009228150A1 (https=)
BR (1) BRPI0910241A2 (https=)
CA (1) CA2718608A1 (https=)
MX (1) MX2010010455A (https=)
TW (1) TW200946541A (https=)
WO (1) WO2009120914A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526332A (ja) * 2015-07-02 2018-09-13 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
US10898540B2 (en) 2016-04-07 2021-01-26 Gem Vax & KAEL Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
US10960056B2 (en) 2012-05-11 2021-03-30 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
US11077163B2 (en) 2014-12-23 2021-08-03 Gemvax & Kael Co., Ltd. Peptide for treating ocular diseases and composition for treating ocular diseases comprising same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012114352A2 (en) * 2011-02-21 2012-08-30 Hetero Research Foundation Pharmaceutical compositions of maraviroc and process for the preparation thereof

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US4328245A (en) * 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) * 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) * 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4797286A (en) * 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
CA2079912C (en) * 1990-04-06 2000-07-11 Gregory Reyes Hepatitis c virus epitopes
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
TW224053B (https=) * 1991-09-13 1994-05-21 Paul B Chretien
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
GB9226729D0 (en) * 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
WO1994019012A2 (en) * 1993-02-24 1994-09-01 Wang Jui H Compositions and methods of application of reactive antiviral polymers
WO1995003056A1 (en) * 1993-07-19 1995-02-02 Tokyo Tanabe Company Limited Hepatitis c virus proliferation inhibitor
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
KR960705579A (ko) 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
DE4415539C2 (de) * 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Pflanzen mit virustatischer und antiviraler Wirkung
DE4432623A1 (de) * 1994-09-14 1996-03-21 Huels Chemische Werke Ag Verfahren zur Bleichung von wäßrigen Tensidlösungen
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5783846A (en) * 1995-09-22 1998-07-21 Hughes Electronics Corporation Digital circuit with transistor geometry and channel stops providing camouflage against reverse engineering
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
JP2000506010A (ja) * 1996-02-29 2000-05-23 イミューソル インコーポレイテッド Ｃ型肝炎ウイルスリボザイム
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5990276A (en) * 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
US5891874A (en) * 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5837257A (en) * 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
JP3927630B2 (ja) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウイルス感染症の予防・治療剤
US5922757A (en) * 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6004933A (en) * 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
UA61962C2 (uk) * 1997-06-30 2003-12-15 Мерц Фарма Гмбх Унд Ко. Кгаа Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
DK1136075T3 (da) 1997-09-21 2003-04-28 Schering Corp Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6350458B1 (en) * 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
KR100719606B1 (ko) 1998-02-25 2007-05-17 에모리 유니버시티 2'-플루오로뉴클레오사이드
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
CA2331823A1 (en) 1998-05-15 1999-11-25 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
CZ298681B6 (cs) 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
ES2255295T3 (es) 1998-08-10 2006-06-16 Idenix (Cayman) Limited 2'-deoxi-beta-l-nucleosidos para el tratamiento de la hepatitis b.
AR021876A1 (es) 1998-12-18 2002-08-07 Schering Corp Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
EP1964569A3 (en) 2000-04-13 2009-07-22 Pharmasset, Inc. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
MY141594A (en) 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
SK742003A3 (en) 2000-07-21 2003-06-03 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP1326594A2 (en) 2000-10-18 2003-07-16 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
ES2263687T3 (es) 2000-11-20 2006-12-16 Bristol-Myers Squibb Company Inhibidores tripeptidicos de la hepatitis c.
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
WO2002048157A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
WO2002048165A2 (en) 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
WO2003024461A1 (en) 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
ITMI20021399A1 (it) 2002-06-25 2003-12-29 Nicox Sa Inibitori della cicloossigenasi 2
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
BR0312271A (pt) 2002-06-28 2007-11-06 Idenix Cayman Ltd compostos, composições e seus usos para o tratamento de infecções por flaviviridae
PL374781A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AU2003258145A1 (en) 2002-08-07 2004-02-25 Idenix (Cayman) Limited Substituted phenylindoles for the treatment of hiv
DE602005011031D1 (en) 2004-09-17 2008-12-24 Idenix Pharmaceuticals Inc Phosphoindole als hiv-inhibitoren
WO2007038796A1 (en) 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
KR20090077813A (ko) 2006-09-29 2009-07-15 아이데닉스 파마슈티칼스, 인코포레이티드 Ｈｉｖ 억제제로서의 거울상이성질체적으로 순수한 포스포인돌

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11369665B2 (en) 2012-05-11 2022-06-28 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US12156902B2 (en) 2012-05-11 2024-12-03 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US12168039B2 (en) 2012-05-11 2024-12-17 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US10960056B2 (en) 2012-05-11 2021-03-30 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US11857607B2 (en) 2012-05-11 2024-01-02 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
US11077163B2 (en) 2014-12-23 2021-08-03 Gemvax & Kael Co., Ltd. Peptide for treating ocular diseases and composition for treating ocular diseases comprising same
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
JP2021175746A (ja) * 2015-07-02 2021-11-04 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
JP2018526332A (ja) * 2015-07-02 2018-09-13 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
JP7218403B2 (ja) 2015-07-02 2023-02-06 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
US10898540B2 (en) 2016-04-07 2021-01-26 Gem Vax & KAEL Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same

Also Published As

Publication number Publication date
TW200946541A (en) 2009-11-16
MX2010010455A (es) 2011-03-21
US8470870B2 (en) 2013-06-25
US20110039803A1 (en) 2011-02-17
EP2276771A1 (en) 2011-01-26
CA2718608A1 (en) 2009-10-01
BRPI0910241A2 (pt) 2015-09-29
WO2009120914A1 (en) 2009-10-01
AU2009228150A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
ES2488922T3 (es) Fosfoindoles enantiómeramente puros como inhibidores del HIV
TWI771621B (zh) 整合應激路徑之前藥調節劑
TWI813596B (zh) 整合應激路徑之調節劑
JP2011515498A (ja) 抗ｈｉｖホスホインドール化合物の固体形態
US8163707B2 (en) 4′-allene-substituted nucleoside derivatives
JP6980649B2 (ja) イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
BRPI0621027A2 (pt) composto, composição farmacêutica
TW201615636A (zh) 苯甲基取代吲唑
JP2008523098A (ja) ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体
US20090274686A1 (en) Nucleoside phosphonate derivatives
CN114364674B (zh) 吡唑化合物，其配制品以及使用所述化合物和/或配制品的方法
JP2006500355A (ja) Ｈｉｖ治療用の置換フェニルインドール類
CN108239074A (zh) 喹唑啉类化合物及其制备方法、用途和药物组合物
US12251394B2 (en) Methods for the treatment of bladder cancer
CN101627044A (zh) 作为hiv抑制剂的对映体纯的膦酰吲哚
CN121270511A (zh) 4-甲基喹唑啉类衍生物及其制备方法、用途和药物组合物
BR112019017084A2 (pt) compostos dinucleotídeos cíclicos para o tratamento do câncer
HK1129679B (en) Enantiomerically pure phosphoindole as hiv inhibitor
BR112019017084B1 (pt) Compostos dinucleotídeos cíclicos, composições farmacêuticas que compreendem os mesmos e uso dos ditos compostos para o tratamento de câncer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120326

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20130917